Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: rigosertib

Sponsor

Traws Pharma, Inc.